Japanese breast cancer survival data reviewed for palbociclib combo
NCT ID NCT04735367
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study in Japan reviewed medical records of 42 patients with HR+/HER2- advanced breast cancer who had been treated with palbociclib plus letrozole. The goal was to see how long patients lived after starting this treatment. It was a follow-up to an earlier phase 2 study and did not involve any new treatments or procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palbociclib plus letrozole
What this could lead to
If successful, this study could confirm the real-world survival benefit of this drug combination for Japanese patients with advanced breast cancer.
What could go wrong
This is a small, retrospective observational study with only 42 patients, so results may not apply to broader populations. It does not test a new treatment, only reviews past data.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center
Nagoya, 464-8681, Japan
-
Chiba cancer center
Chiba, Chiba, 260-8717, Japan
-
Hakuaikai Medical Corporation Sagara Hospital
Kagoshima, 892-0833, Japan
-
Hiroshima City Hiroshima Citizens Hospital
Hiroshima, Hiroshima, 730-8518, Japan
-
Kumamoto Shinto General Hospital
Kumamoto, 862-8655, Japan
-
Kumamoto University Hospital
Kumamoto, Kumamoto, 860-8556, Japan
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
National Cancer Center Hospital
Chuo-ku, Tokyo, 104-0045, Japan
-
National Hospital Organization - Osaka National Hospital - Institute For Clinical Research
Osaka, 540-0006, Japan
-
National Hospital Organization Hokkaido Cancer Center
Sapporo, Hokkaido, 003-0804, Japan
-
National Hospital Organization Kyushu Cancer Center
Fukuoka, 811-1395, Japan
-
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, 791-0280, Japan
-
Saitama Cancer Center
Kita-adachi-gun, Saitama, 362-0806, Japan